vs

Side-by-side financial comparison of PRA GROUP INC (PRAA) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

PRA GROUP INC is the larger business by last-quarter revenue ($333.4M vs $197.9M, roughly 1.7× REPLIGEN CORP). PRA GROUP INC runs the higher net margin — 17.0% vs 6.7%, a 10.2% gap on every dollar of revenue. On growth, PRA GROUP INC posted the faster year-over-year revenue change (13.7% vs 13.6%). REPLIGEN CORP produced more free cash flow last quarter ($17.6M vs $-90.4M). Over the past eight quarters, REPLIGEN CORP's revenue compounded faster (14.4% CAGR vs 14.2%).

PRA Group, Inc. is a publicly traded debt buyer and debt collection company based in Norfolk, Virginia. The company buys delinquent consumer debt from credit card issuers and other financial institutions at a discount and pursues collection of the full debt owed. Founded in 1996, PRA Group employs more than 3200 people in 18 countries.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

PRAA vs RGEN — Head-to-Head

Bigger by revenue
PRAA
PRAA
1.7× larger
PRAA
$333.4M
$197.9M
RGEN
Growing faster (revenue YoY)
PRAA
PRAA
+0.0% gap
PRAA
13.7%
13.6%
RGEN
Higher net margin
PRAA
PRAA
10.2% more per $
PRAA
17.0%
6.7%
RGEN
More free cash flow
RGEN
RGEN
$107.9M more FCF
RGEN
$17.6M
$-90.4M
PRAA
Faster 2-yr revenue CAGR
RGEN
RGEN
Annualised
RGEN
14.4%
14.2%
PRAA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PRAA
PRAA
RGEN
RGEN
Revenue
$333.4M
$197.9M
Net Profit
$56.5M
$13.3M
Gross Margin
52.5%
Operating Margin
37.7%
9.0%
Net Margin
17.0%
6.7%
Revenue YoY
13.7%
13.6%
Net Profit YoY
206.3%
143.9%
EPS (diluted)
$1.47
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRAA
PRAA
RGEN
RGEN
Q4 25
$333.4M
$197.9M
Q3 25
$311.1M
$188.8M
Q2 25
$287.7M
$182.4M
Q1 25
$269.6M
$169.2M
Q4 24
$293.2M
$174.1M
Q3 24
$281.5M
$154.9M
Q2 24
$284.2M
$154.1M
Q1 24
$255.6M
$151.3M
Net Profit
PRAA
PRAA
RGEN
RGEN
Q4 25
$56.5M
$13.3M
Q3 25
$-407.7M
$14.9M
Q2 25
$42.4M
$14.9M
Q1 25
$3.7M
$5.8M
Q4 24
$18.5M
$-30.3M
Q3 24
$27.2M
$-654.0K
Q2 24
$21.5M
$3.3M
Q1 24
$3.5M
$2.1M
Gross Margin
PRAA
PRAA
RGEN
RGEN
Q4 25
52.5%
Q3 25
53.2%
Q2 25
50.0%
Q1 25
53.6%
Q4 24
26.1%
Q3 24
50.0%
Q2 24
49.8%
Q1 24
49.5%
Operating Margin
PRAA
PRAA
RGEN
RGEN
Q4 25
37.7%
9.0%
Q3 25
-101.4%
8.9%
Q2 25
29.6%
7.6%
Q1 25
27.7%
3.9%
Q4 24
32.1%
-17.7%
Q3 24
32.0%
-5.1%
Q2 24
31.4%
1.0%
Q1 24
26.0%
1.3%
Net Margin
PRAA
PRAA
RGEN
RGEN
Q4 25
17.0%
6.7%
Q3 25
-131.0%
7.9%
Q2 25
14.7%
8.2%
Q1 25
1.4%
3.4%
Q4 24
6.3%
-17.4%
Q3 24
9.6%
-0.4%
Q2 24
7.6%
2.2%
Q1 24
1.4%
1.4%
EPS (diluted)
PRAA
PRAA
RGEN
RGEN
Q4 25
$1.47
$0.24
Q3 25
$-10.43
$0.26
Q2 25
$1.08
$0.26
Q1 25
$0.09
$0.10
Q4 24
$0.47
$-0.55
Q3 24
$0.69
$-0.01
Q2 24
$0.54
$0.06
Q1 24
$0.09
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRAA
PRAA
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$104.4M
$767.6M
Total DebtLower is stronger
$542.2M
Stockholders' EquityBook value
$979.9M
$2.1B
Total Assets
$5.1B
$2.9B
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRAA
PRAA
RGEN
RGEN
Q4 25
$104.4M
$767.6M
Q3 25
$107.5M
$748.7M
Q2 25
$131.6M
$708.9M
Q1 25
$128.7M
$697.2M
Q4 24
$105.9M
$757.4M
Q3 24
$141.1M
$784.0M
Q2 24
$118.9M
$809.1M
Q1 24
$108.1M
$780.6M
Total Debt
PRAA
PRAA
RGEN
RGEN
Q4 25
$542.2M
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$525.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
PRAA
PRAA
RGEN
RGEN
Q4 25
$979.9M
$2.1B
Q3 25
$928.5M
$2.1B
Q2 25
$1.3B
$2.1B
Q1 25
$1.2B
$2.0B
Q4 24
$1.1B
$2.0B
Q3 24
$1.2B
$2.0B
Q2 24
$1.1B
$2.0B
Q1 24
$1.1B
$2.0B
Total Assets
PRAA
PRAA
RGEN
RGEN
Q4 25
$5.1B
$2.9B
Q3 25
$5.0B
$2.9B
Q2 25
$5.4B
$2.9B
Q1 25
$5.1B
$2.9B
Q4 24
$4.9B
$2.8B
Q3 24
$4.9B
$2.8B
Q2 24
$4.7B
$2.9B
Q1 24
$4.5B
$2.8B
Debt / Equity
PRAA
PRAA
RGEN
RGEN
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRAA
PRAA
RGEN
RGEN
Operating Cash FlowLast quarter
$-85.5M
$25.7M
Free Cash FlowOCF − Capex
$-90.4M
$17.6M
FCF MarginFCF / Revenue
-27.1%
8.9%
Capex IntensityCapex / Revenue
1.4%
4.1%
Cash ConversionOCF / Net Profit
-1.51×
1.93×
TTM Free Cash FlowTrailing 4 quarters
$-169.4M
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRAA
PRAA
RGEN
RGEN
Q4 25
$-85.5M
$25.7M
Q3 25
$-10.1M
$48.1M
Q2 25
$-12.9M
$28.6M
Q1 25
$-52.6M
$15.0M
Q4 24
$-94.6M
$39.2M
Q3 24
$-35.0M
$49.3M
Q2 24
$-29.5M
$42.2M
Q1 24
$-73.0M
$44.7M
Free Cash Flow
PRAA
PRAA
RGEN
RGEN
Q4 25
$-90.4M
$17.6M
Q3 25
$-11.3M
$43.4M
Q2 25
$-14.2M
$21.5M
Q1 25
$-53.5M
$11.4M
Q4 24
$-98.6M
$33.6M
Q3 24
$-36.1M
$42.3M
Q2 24
$-30.8M
$37.4M
Q1 24
$-73.5M
$36.4M
FCF Margin
PRAA
PRAA
RGEN
RGEN
Q4 25
-27.1%
8.9%
Q3 25
-3.6%
23.0%
Q2 25
-4.9%
11.8%
Q1 25
-19.8%
6.8%
Q4 24
-33.6%
19.3%
Q3 24
-12.8%
27.3%
Q2 24
-10.8%
24.3%
Q1 24
-28.8%
24.0%
Capex Intensity
PRAA
PRAA
RGEN
RGEN
Q4 25
1.4%
4.1%
Q3 25
0.4%
2.5%
Q2 25
0.4%
3.9%
Q1 25
0.3%
2.1%
Q4 24
1.4%
3.2%
Q3 24
0.4%
4.5%
Q2 24
0.5%
3.1%
Q1 24
0.2%
5.5%
Cash Conversion
PRAA
PRAA
RGEN
RGEN
Q4 25
-1.51×
1.93×
Q3 25
3.23×
Q2 25
-0.30×
1.92×
Q1 25
-14.37×
2.57×
Q4 24
-5.13×
Q3 24
-1.29×
Q2 24
-1.37×
12.70×
Q1 24
-21.01×
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRAA
PRAA

GB$170.1M51%
Other$163.3M49%

RGEN
RGEN

Segment breakdown not available.

Related Comparisons